CD4 and myeloid sarcoma: Firstly, the studies performed have taken different approaches where MS patient studies on the whole have not differentiated between Teffs and Tregs, instead usually analysing pooled PBMCs or total CD4+ T cells, unlike in EAE, where subpopulation distinctions have been taken into account.